About this trial
Dexmedetomidine is a selective a-2 adrenergic agonist that provides sedative and analgesic effects. Intranasal dexmedetomidine has a slower and gradual onset compared to intravenous injection , with low incidence of nasal discomfort. Dexmedetomidine was tested at various doses and modes of administration, as well as different types of surgery and co-anesthetic drugs, as a single injection or continuous infusion. The authors have not agreed on the ideal clinical dose. The hypothesis is that intranasal dexmedetomidine 3mcg /kg will decrease the incidence of emergence agitation after strabismus surgery than dexmedetomidine 2 mcg/kg
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Age: 3-6 years, both sexes
ASA physical status class I , II.
Disqualifiers
history of neurological and psychiatric disease
body mass index > 20 kg m-2
allergy to dexmedetomidine
patients on medical treatment which has any sedative effect
Trial design
Parallel
Treatments tested in this trial
high dex group
Other interventionpatients will receive 3 mcg/kg intranasal dexmedetomidine 45minutes before surgery
low dex group
Other interventionpatients will receive 2 mcg/kg intranasal dexmedetomidine 45minutes before surgery
Treatment groups
Trial outcomes
Primary outcomes
Incidence of emergence agitation
pediatric anesthesia emergence delirium ( PAED) scale.
Secondary outcomes
Incidence of intraoperative hemodynamic changes
bradycardia and hypotension
Modified Yale Preoperative Anxiety Scale (mYPAS) upon separation from parents
mYPAS
PACU discharge time
minutes
Sponsors and contacts
Click on the lead sponsor to view all of their trials.